This trial has completed recruitment on this platform, and is no longer accepting new referrals.
A clinical trial conducted by Moderna is evaluating investigational booster vaccines that may protect against the COVID-19 Omicron variant and other variants.
Trial ID: mRNA-1273-P305 [EudraCT ID: 2022-000063-51]
The mRNA-1273-P305 clinical trial is evaluating the safety and immune response of the investigational booster vaccines that may protect against the COVID-19 Omicron variant and other variants. The investigational Omicron variant vaccines being studied are being compared to a booster dose of Moderna’s COVID-19 vaccine, SPIKEVAX, which is the vaccine that received conditional marketing authorization in the EU. All participants will receive either an investigational Omicron variant vaccine or SPIKEVAX.
With different strains of COVID-19, there is an urgent need to develop vaccination plans that will provide greater protection. A booster vaccine that protects against COVID-19 variants, including the Omicron variant, would be a crucial public health tool to help curb the pandemic.
Participation in this clinical trial lasts up to 13 months and includes phone calls and visits to the trial site.
Insurance is not needed to join this clinical trial, and compensation for participant’s time/travel will be available.
You will need to travel to one of the study clinics taking part in this clinical trial.
Sites are located in the cities/states identified with the red pin: